The Data: In 2026, a major Cochrane systematic review of 22 randomized trials found that intermittent fasting produced only modest results (average 25% weight loss), while semaglutide users typically see 15% to 20% reduction in total body weight
While gastrointestinal symptoms dominate the adverse effect profile, patients and clinicians have increasingly questioned whether these medications might contribute to musculoskeletal complaints, including muscle pain, weakness, or discomfort
Metabolism Changes A calorie deficit can lead to weight loss, but too much too soon can have negative consequences
The study found that semaglutide helped lower the risk of major heart events like heart attack, stroke, or death from heart problems
It is also approved by the FDA as a newer class of treatments for diabetes
(2020) Posted on: March 31, 2020 Kaged Muscle Stim-Free Pre-Kaged Kicks the Caffeine Posted on: March 17, 2020 InnovaPharm MVPre 2.0: Award-Winning Pre Workout Comes to the US